Alane Barnes Sells 50,906 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider Alane Barnes sold 50,906 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $7.21, for a total value of $367,032.26. Following the sale, the insider directly owned 365,246 shares of the company’s stock, valued at approximately $2,633,423.66. The trade was a 12.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $7.83 on Friday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.31. The firm’s 50 day moving average price is $7.13 and its two-hundred day moving average price is $8.37. The firm has a market cap of $1.65 billion, a P/E ratio of -156.60 and a beta of 0.91.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The company had revenue of $159.40 million for the quarter, compared to the consensus estimate of $162.91 million. During the same period in the prior year, the company earned ($0.07) EPS. The firm’s revenue was up 36.1% on a year-over-year basis. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC acquired a new position in BioCryst Pharmaceuticals during the first quarter worth approximately $32,000. New Age Alpha Advisors LLC bought a new position in shares of BioCryst Pharmaceuticals during the 1st quarter worth approximately $62,000. Family Legacy Financial Solutions LLC acquired a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth approximately $72,000. Focus Partners Wealth bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at $77,000. Finally, Farther Finance Advisors LLC raised its stake in BioCryst Pharmaceuticals by 326.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 8,109 shares during the period. Institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on BCRX shares. Zacks Research downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. JMP Securities boosted their target price on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a research note on Wednesday, October 15th. TD Cowen began coverage on BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target for the company. Evercore ISI reiterated an “in-line” rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.